Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma.
Mizuno T, Harada K, Ichimata M, Katayama R, Kato Y, Shiga T, Tsukui T, Toyoda H, Fukazawa E, Matsuyama F, Igase M, Kobayashi T · Journal of Veterinary Internal Medicine · 21 January 2026
Anti-CD20 antibody with CHOP chemotherapy shows promising results in canine B-cell lymphoma.
This study evaluated a novel afucosylated anti-canine CD20 antibody (4E1-7-B_f) combined with CHOP chemotherapy in 13 dogs with untreated high-grade B-cell lymphoma. All dogs achieved complete response with a median time to CR of 3 weeks. Median progression-free survival was 340 days and overall survival was 458 days, with 1- and 2-year survival rates of 69.2% and 38.9%, respectively. B-cell depletion was sustained for over 200 days in most dogs, with some remaining B-cell deficient beyond 300 days. Adverse events were predominantly mild to moderate. While this single-arm trial demonstrates promising efficacy and tolerability compared to historical CHOP data, the authors acknowledge limitations in study design and emphasize the need for randomized controlled trials to confirm potential benefits of CD20-targeted immunotherapy in canine B-cell lymphoma.
This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.